Proteases - Lung Cancer - HIV
Proteases, also known as peptidases or proteolytic enzymes, consists of a large number of enzymes catalyzing the hydrolysis of peptide bonds and subsequently resulting in the degradation of protein substrates into amino acids. Proteases are involved in a wide range of human diseases, including cancer, neurodegenerative disorders, inflammatory diseases and cardiovascular diseases. Thus numerous proteases inhibitors (small molecules and proteins) have been identified to block activity of proteases. Proteases inhibitors can be classified into different types based on the class of proteases they inhibit through two general mechanisms, irreversible “trapping” reactions and reversible tight-binding reactions. Proteases inhibitors have been used as diagnostic or therapeutic agents for the treatment of proteases-related diseases.
- B3941 Talabostat mesylate2 CitationTarget: DPP-4Summary: DPP4抑制剂
- A3253 BMS-6265292 CitationTarget: HIV-1 gp120Summary: HIV-1吸附的抑制剂
- A8203 Ritonavir中文名: 利托那韦Summary: HIV蛋白酶抑制剂
- A4073 Raltegravir (MK-0518)1 Citation中文名: 拉替拉韦,雷特格韦Target: integraseSummary: HIV-1整合酶抑制剂
- A4070 Elvitegravir (GS-9137)中文名: 埃替格韦Target: HIV IntegrasesSummary: HIV-1整合酶抑制剂
- A4064 NVP-BEP800Target: HSP90Summary: 全合成的HSP90β口服抑制剂
- A4061 IPI-504 (Retaspimycin hydrochloride)3 Citation中文名: 瑞他霉素盐酸盐Target: HSP90Summary: Hsp90抑制剂